HRP20090565T1 - Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže - Google Patents
Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20090565T1 HRP20090565T1 HR20090565T HRP20090565T HRP20090565T1 HR P20090565 T1 HRP20090565 T1 HR P20090565T1 HR 20090565 T HR20090565 T HR 20090565T HR P20090565 T HRP20090565 T HR P20090565T HR P20090565 T1 HRP20090565 T1 HR P20090565T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- group
- formula
- amino
- pharmaceutically acceptable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 125000003118 aryl group Chemical group 0.000 claims abstract 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 16
- 229910052757 nitrogen Chemical group 0.000 claims abstract 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 239000001301 oxygen Substances 0.000 claims abstract 8
- 239000011593 sulfur Chemical group 0.000 claims abstract 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 8
- 125000002619 bicyclic group Chemical group 0.000 claims abstract 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 5
- 125000005843 halogen group Chemical group 0.000 claims abstract 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract 3
- 125000003277 amino group Chemical group 0.000 claims abstract 3
- 125000000732 arylene group Chemical group 0.000 claims abstract 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract 3
- 125000005549 heteroarylene group Chemical group 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000005110 aryl thio group Chemical group 0.000 claims abstract 2
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract 2
- 125000005368 heteroarylthio group Chemical group 0.000 claims abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 2
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 229930192474 thiophene Natural products 0.000 claims abstract 2
- -1 hydroxy, carboxy, formyl Chemical group 0.000 claims 18
- 239000002253 acid Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 238000000926 separation method Methods 0.000 claims 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000007822 coupling agent Substances 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 231100000024 genotoxic Toxicity 0.000 claims 1
- 230000001738 genotoxic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 125000006684 polyhaloalkyl group Polymers 0.000 claims 1
- 230000000861 pro-apoptotic effect Effects 0.000 claims 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0700741A FR2912145B1 (fr) | 2007-02-02 | 2007-02-02 | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090565T1 true HRP20090565T1 (hr) | 2009-12-31 |
Family
ID=38219469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090565T HRP20090565T1 (hr) | 2007-02-02 | 2009-10-22 | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže |
Country Status (45)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2064175B1 (fr) | 2006-09-07 | 2014-08-06 | F. Hoffmann-La Roche AG | Procede de fabrication de snac (salcaprozate sodium) |
| FR2933983B1 (fr) * | 2008-07-15 | 2010-08-27 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| ES2568262T3 (es) * | 2009-04-23 | 2016-04-28 | Abbvie Inc. | Moduladores de receptores de 5-HT y sus métodos de uso |
| US8546377B2 (en) * | 2009-04-23 | 2013-10-01 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| AU2010294292B2 (en) * | 2009-09-10 | 2013-07-18 | Novartis Ag | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer |
| CN102584744B (zh) * | 2011-01-06 | 2015-07-01 | 上海药明康德新药开发有限公司 | 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法 |
| CN104039797B (zh) | 2011-10-12 | 2016-06-01 | 南京奥昭生物科技有限公司 | 作为细胞凋亡诱导剂的杂环分子 |
| TWI620733B (zh) | 2013-05-21 | 2018-04-11 | 拜耳作物科學股份有限公司 | 製備特定肟類及肟醚類之改良方法 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899490A (en) * | 1968-01-12 | 1975-08-12 | Pfizer | Hexahydro pyrazinoquinolines |
| DE2362539C2 (de) * | 1973-12-17 | 1986-05-07 | Merck Patent Gmbh, 6100 Darmstadt | 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5688950A (en) * | 1996-04-23 | 1997-11-18 | Neurogen Corporation | Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands |
| JP2000169475A (ja) * | 1998-07-24 | 2000-06-20 | Dai Ichi Seiyaku Co Ltd | ピラゾ―ル誘導体およびその塩 |
| US6180629B1 (en) * | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
| US6190629B1 (en) | 1999-04-16 | 2001-02-20 | Cbl Technologies, Inc. | Organic acid scrubber and methods |
| US7919493B2 (en) * | 2000-04-12 | 2011-04-05 | Pharma Mar, S.A. | Anititumoral ecteinascidin derivatives |
| AU2001283955B2 (en) * | 2000-07-31 | 2006-05-18 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
| ES2320980T3 (es) * | 2001-11-03 | 2009-06-01 | Astrazeneca Ab | Derivados de quinazolina como agentes antitumorales. |
| NZ533649A (en) * | 2001-12-21 | 2006-01-27 | King Pharmaceuticals Res & Dev | Tyrosyl derivatives and their use as P2X7 receptor modulators |
| FR2841243B1 (fr) * | 2002-06-19 | 2004-08-20 | Servier Lab | Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7135480B2 (en) * | 2002-12-12 | 2006-11-14 | Cytovia, Inc. | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis |
| WO2005049593A2 (fr) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
| JP4734119B2 (ja) * | 2004-02-12 | 2011-07-27 | 田辺三菱製薬株式会社 | インダゾール化合物及びその医薬用途 |
| US7790712B2 (en) * | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| EP2249818A4 (fr) * | 2008-02-12 | 2011-09-07 | Univ Stanford | Antagonistes de la voie hedgehog et méthodes d utilisation |
-
2007
- 2007-02-02 FR FR0700741A patent/FR2912145B1/fr not_active Expired - Fee Related
-
2008
- 2008-01-23 PE PE2008000167A patent/PE20081703A1/es not_active Application Discontinuation
- 2008-01-24 US US12/011,225 patent/US20080188460A1/en not_active Abandoned
- 2008-01-28 GE GEAP200810489A patent/GEP20115186B/en unknown
- 2008-01-28 MY MYPI20080152A patent/MY144633A/en unknown
- 2008-01-28 MA MA30601A patent/MA29725B1/fr unknown
- 2008-01-29 UA UAA200801063A patent/UA90726C2/ru unknown
- 2008-01-30 SA SA08290043A patent/SA08290043B1/ar unknown
- 2008-01-31 MX MX2008001504A patent/MX2008001504A/es active IP Right Grant
- 2008-01-31 SG SG200800896-3A patent/SG144892A1/en unknown
- 2008-01-31 BR BRPI0800988-0A patent/BRPI0800988A2/pt not_active IP Right Cessation
- 2008-02-01 JP JP2008022515A patent/JP2008266296A/ja active Pending
- 2008-02-01 WO PCT/FR2008/000121 patent/WO2008110691A1/fr active Application Filing
- 2008-02-01 DK DK08290088T patent/DK1953161T3/da active
- 2008-02-01 CA CA2619897A patent/CA2619897C/fr not_active Expired - Fee Related
- 2008-02-01 AP AP2009004945A patent/AP2009004945A0/xx unknown
- 2008-02-01 ZA ZA200801103A patent/ZA200801103B/xx unknown
- 2008-02-01 TW TW097104070A patent/TW200838532A/zh unknown
- 2008-02-01 AR ARP080100421A patent/AR065131A1/es unknown
- 2008-02-01 SI SI200830004T patent/SI1953161T1/sl unknown
- 2008-02-01 PA PA20088768301A patent/PA8768301A1/es unknown
- 2008-02-01 DE DE602008000104T patent/DE602008000104D1/de active Active
- 2008-02-01 EA EA200800235A patent/EA014672B1/ru not_active IP Right Cessation
- 2008-02-01 EP EP08290088A patent/EP1953161B1/fr active Active
- 2008-02-01 AU AU2008200499A patent/AU2008200499A1/en not_active Abandoned
- 2008-02-01 PT PT08290088T patent/PT1953161E/pt unknown
- 2008-02-01 AT AT08290088T patent/ATE440842T1/de active
- 2008-02-01 NZ NZ565643A patent/NZ565643A/en unknown
- 2008-02-01 PL PL08290088T patent/PL1953161T3/pl unknown
- 2008-02-01 ES ES08290088T patent/ES2332337T3/es active Active
- 2008-02-01 CL CL200800318A patent/CL2008000318A1/es unknown
- 2008-02-01 KR KR1020080010639A patent/KR100997027B1/ko not_active IP Right Cessation
- 2008-02-01 RS RSP-2009/0449A patent/RS51133B/sr unknown
- 2008-02-02 CN CNA2008100963808A patent/CN101270120A/zh active Pending
- 2008-02-02 JO JOP/2008/0039A patent/JO2616B1/ar active
-
2009
- 2009-07-23 TN TNP2009000307A patent/TN2009000307A1/fr unknown
- 2009-07-24 CR CR10953A patent/CR10953A/es unknown
- 2009-07-28 IL IL200128A patent/IL200128A0/en unknown
- 2009-07-28 EC EC2009009546A patent/ECSP099546A/es unknown
- 2009-07-29 NI NI200900147A patent/NI200900147A/es unknown
- 2009-07-31 CO CO09080210A patent/CO6230990A2/es not_active Application Discontinuation
- 2009-07-31 GT GT200900217A patent/GT200900217A/es unknown
- 2009-07-31 SV SV2009003348A patent/SV2009003348A/es unknown
- 2009-10-22 HR HR20090565T patent/HRP20090565T1/hr unknown
- 2009-11-24 CY CY20091101213T patent/CY1109637T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| ES2666870T3 (es) | Derivado de dispiropirrolidina | |
| JP7158383B2 (ja) | Ｃ－ｋｉｔ阻害剤としてのベンズイミダゾール化合物 | |
| ES2819448T3 (es) | Tetrahidro-pirido[3,4-b]indoles como moduladores del receptor de estrógenos y usos de los mismos | |
| JP6898868B2 (ja) | Ｈｐｋ１阻害剤およびそれを用いる方法 | |
| RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
| RU2014134388A (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| ES2834027T3 (es) | Compuestos de N-pirrolidinil, N'-pirazolil-urea como inhibidores de TrkA quinasa | |
| RU2607788C2 (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP2021534124A (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６−（４−アミノ−３−メチル−２−オキサ−８−アザスピロ［４．５］デカン−８−イル）−３−（２，３−ジクロロフェニル）−２−メチルピリミジン−４（３ｈ）−オン誘導体及び関連化合物 | |
| KR20190091537A (ko) | C-kit 억제제로서의 아미노티아졸 화합물 | |
| AU2012204982B2 (en) | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | |
| JP2019518059A (ja) | ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体 | |
| CA2828478A1 (fr) | Inhibiteurs de serine/threonine kinase | |
| JP6386467B2 (ja) | キナーゼ活性のモジュレーターとしての新規複素環式誘導体 | |
| RU2019143759A (ru) | Новое соединение бифенила или его соль | |
| RU2014130129A (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| DK3027602T3 (en) | NEW INDO AND PYROL RELEASE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| KR20220086628A (ko) | Prmt5 저해제의 약학적 조합물 | |
| AU2015222805A1 (en) | Treatment of conditions associated with hyperinsulinaemia | |
| CA3012882A1 (fr) | Derives de cycles condenses de parazole et procede de preparation de ces derniers, et application de ces derniers dans le traitement de cancers, d'inflammation et de maladies immunitaires | |
| JP2021107456A (ja) | インドリノン化合物の使用 | |
| DOP2013000009A (es) | Derivados heterociclicos fusionados como moduladores s1p | |
| CN112672997A (zh) | 哒嗪酮衍生物 |